EXCENEL FLOW, 50 MG/ML, SUSPENSION FOR INJECTION FOR PIGS AND CATTLE

País: Irlanda

Língua: inglês

Origem: HPRA (Health Products Regulatory Authority)

Ingredientes ativos:

CEFTIOFUR (AS HYDROCHLORIDE)

Disponível em:

Zoetis Ireland Limited

Código ATC:

QJ01DD90

DCI (Denominação Comum Internacional):

CEFTIOFUR (AS HYDROCHLORIDE)

Dosagem:

50 Mg/Ml

Forma farmacêutica:

Suspension for Injection

Tipo de prescrição:

POM

Grupo terapêutico:

Bovine, Porcine

Área terapêutica:

Ceftiofur

Indicações terapêuticas:

Antibacterial

Status de autorização:

Authorised

Data de autorização:

2013-12-09

Características técnicas

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Excenel Flow, 50 mg/ml, suspension for injection for pigs and cattle
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
ACTIVE SUBSTANCE:
Ceftiofur (as hydrochloride)
50.0 mg
EXCIPIENT(S):
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Suspension for injection.
Opaque suspension, white to off-white.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Pigs and cattle.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Infections associated with bacteria sensitive to ceftiofur:
In pigs:
For the treatment of bacterial respiratory disease associated with_
Pasteurella multocida_,_ Actinobacillus_
_pleuropneumoniae_ and_ Streptococcus suis_.
In cattle:
For the treatment of bacterial respiratory disease associated with_
Mannheimia haemolytica_ (former_ Pasteurella_
_haemolytica_),_ Pasteurella multocida_ and_ Histophilus somni_
(former_ Haemophilus somnus_).
For the treatment of acute interdigital necrobacillosis (panaritium,
foot rot), associated with_ Fusobacterium_
_necrophorum_ and_ Bacteroides melaninogenicus_ (_Porphyromonas
asaccharolytica_).
For treatment of the bacterial component of acute post-partum
(puerperal) metritis within 10 days after calving
associated with_ Escherichia coli_,_ Arcanobacterium pyogenes_ and_
Fusobacterium necrophorum_, sensitive to ceftiofur,
were treatment with another antimicrobial has failed.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_7